title: Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
authors.affiliation: Robarts Research Institute, The University of Western Ontario, London, ON, Canada. bfeagan@robarts.ca
authors.forename: B G
authors.initials: BG
authors.lastname: Feagan
authors.forename: M C
authors.initials: MC
authors.lastname: Reilly
authors.forename: L
authors.initials: L
authors.lastname: Gerlier
authors.forename: Y
authors.initials: Y
authors.lastname: Brabant
authors.forename: M
authors.initials: M
authors.lastname: Brown
authors.forename: S
authors.initials: S
authors.lastname: Schreiber
mesh_terms: D000041:Absenteeism; D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D004526:Efficiency; D004651:Employment; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol